Preoperative TARE delivers survival comparable to upfront resection in HCC beyond Milan, while TACE is inferior

For resectable HCC beyond Milan criteria, preoperative transarterial radioembolization (TARE) achieved overall survival comparable to primary resection (aHR 1.14, 95% CI 0.50-2.55), whereas transarterial chemoembolization (TACE) had worse OS (aHR 2.72, 95% CI 1.39-5.33).

• Median OS was not reached for primary resection or preoperative TARE, but was 60.7 months for preoperative TACE.
• Recurrence outcomes (TTR and RFS) with TARE were similar to resection, while TACE had significantly worse recurrence (both p=0.02).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.